Hirai, H.; Higa, M.; Morimoto, T.; Sakuma, M.; Arasaki, O.; Nomiyama, T.; Node, K.; Ueda, S.; Shimabukuro, M.
Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) Trial. J. Clin. Med. 2020, 9, 93.
https://doi.org/10.3390/jcm9010093
AMA Style
Hirai H, Higa M, Morimoto T, Sakuma M, Arasaki O, Nomiyama T, Node K, Ueda S, Shimabukuro M.
Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) Trial. Journal of Clinical Medicine. 2020; 9(1):93.
https://doi.org/10.3390/jcm9010093
Chicago/Turabian Style
Hirai, Hiroyuki, Moritake Higa, Takeshi Morimoto, Mio Sakuma, Osamu Arasaki, Takashi Nomiyama, Koichi Node, Shinichiro Ueda, and Michio Shimabukuro.
2020. "Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) Trial" Journal of Clinical Medicine 9, no. 1: 93.
https://doi.org/10.3390/jcm9010093
APA Style
Hirai, H., Higa, M., Morimoto, T., Sakuma, M., Arasaki, O., Nomiyama, T., Node, K., Ueda, S., & Shimabukuro, M.
(2020). Dissimilar Effects of Anagliptin and Sitagliptin on Lipoprotein Subclass in Standard or Strong Statin-Treated Patients with Type-2 Diabetes Mellitus: A Subanalysis of the REASON (Randomized Evaluation of Anagliptin versus Sitagliptin on Low-Density LipoproteiN Cholesterol in Diabetes) Trial. Journal of Clinical Medicine, 9(1), 93.
https://doi.org/10.3390/jcm9010093
